Cornerstone Capital Management Holdings LLC. lowered its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 6.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,090 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Cornerstone Capital Management Holdings LLC.’s holdings in FibroGen were worth $1,456,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of FibroGen by 96.9% during the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after buying an additional 1,641,423 shares in the last quarter. EcoR1 Capital LLC grew its holdings in shares of FibroGen by 3,674.1% during the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock worth $51,210,000 after buying an additional 1,543,448 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of FibroGen during the second quarter worth about $45,633,000. Eagle Asset Management Inc. bought a new position in shares of FibroGen during the third quarter worth about $46,158,000. Finally, Vanguard Group Inc. grew its holdings in shares of FibroGen by 15.1% during the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after buying an additional 761,421 shares in the last quarter. 57.37% of the stock is currently owned by institutional investors.
FGEN has been the subject of a number of research reports. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Jefferies Group reiterated a “buy” rating and set a $75.00 price objective on shares of FibroGen in a report on Tuesday, September 12th. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Thursday. Mizuho restated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. Finally, ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $65.67.
In related news, Director Thomas F. Kearns, Jr. sold 18,000 shares of FibroGen stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $45.22, for a total transaction of $813,960.00. Following the completion of the sale, the director now directly owns 156,564 shares of the company’s stock, valued at approximately $7,079,824.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider K Peony Yu sold 40,000 shares of FibroGen stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $54.63, for a total value of $2,185,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 346,346 shares of company stock valued at $17,855,633. Insiders own 13.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/23/fibrogen-inc-fgen-shares-sold-by-cornerstone-capital-management-holdings-llc.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.